Skip to main content
Clinical Trials/NCT02388217
NCT02388217
Completed
Not Applicable

The Effect of Cannabis on Pain and Related Quality Of Life Outcomes In Chronic Pain: A Prospective Open-Label Study

Hadassah Medical Organization1 site in 1 country400 target enrollmentApril 2013
ConditionsChronic Pain

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Pain
Sponsor
Hadassah Medical Organization
Enrollment
400
Locations
1
Primary Endpoint
Change from baseline on the S-TOPS pain symptom scale
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The objective of the current study is to prospectively assess the effect of cannabis on pain and functional outcomes in a large group of patients with chronic pain.

Detailed Description

This is a prospective, observational, open-label study carried out at the ambulatory pain clinic of Hadassah-Hebrew University Medical Center Pain Relief Unit. Study population: Patients suffering from chronic pain that has not been relieved with other analgesic medications, who are eligible for treatment with medical cannabis (cigarettes, oil or cookies) following approval of Israeli Ministry of health.The patients will receive a prescription to be dispensed at pre-approved cannabis distribution points by a certified provider. In this study, the efficacy of the cannabis treatment on pain and related quality of life (QoL) outcomes will be assessed by administering the S-TOPS questionnaire (Haroutiunian, Pain 2012), and the Brief Pain Inventory (BPI) before the treatment (baseline), and on expected follow-up visits at approximately 6 and 12 months.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
November 1, 2020
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Elyad Davidson

MD

Hadassah Medical Organization

Eligibility Criteria

Inclusion Criteria

  • Age \>18 years old
  • Chronic pain, with duration of 3 months or longer
  • Lack of satisfactory analgesic response or intolerable adverse effects with at least two analgesics from 2 different drug classes at full dose.

Exclusion Criteria

  • Inability to read and understand the informed consent form.
  • History of drug abuse/dependence
  • Psychiatric co morbidity (or history) of schizophrenia or acute psychosis.
  • Family history of schizophrenia.
  • Psychologist evaluation of high abuse risk.

Outcomes

Primary Outcomes

Change from baseline on the S-TOPS pain symptom scale

Time Frame: 1 year

The primary outcome is pain reduction (change from baseline) assessed by the Pain Symptom scale of the S-TOPS instrument

Secondary Outcomes

  • Change from baseline on S-TOPS emotional/social disability scales(6 and 12 months)
  • Change from baseline on S-TOPS satisfaction scales(6 and 12 months)
  • Change from baseline on SLP9 sleep disability scale(6 and 12 months)
  • Change from baseline on BPI severity/interference scales(6 and 12 months)
  • Change from baseline on S-TOPS physical disability scales(6 and 12 months)

Study Sites (1)

Loading locations...

Similar Trials